At this years’ virtual annual ASCO meeting, a wide range of interesting studies in the field of gastrointestinal (GI) cancer were presented. The aim of this overview is to discuss the most important of these studies, with a particular focus on data that have the potential to be practice changing. For practical reasons, this report will not follow the traditional subdivision in cancers from the upper and lower GI tract, but will rather focus on three major therapeutic strategies: neoadjuvant therapy, immunotherapy and targeted therapy.

(BELG J MED ONCOL 2020;14(5):183-7)